In its latest quarterly filing, Vivos Therapeutics underscored ongoing operational transitions as it strives to meet Nasdaq’s equity requirements through recent equity raises, while scaling a novel business model focused on acquisition and management of sleep medical practices. The firm’s proprietary oral appliances and The Vivos Method remain central, but the shift toward medical service organizations (MSOs) and dental service organizations (DSOs) branded as Sleep and Airway Medicine Centers (SAMC) represents a strategic repositioning targeting higher-margin healthcare services revenue alongside device sales. This transformation aims to broaden patient access and deepen provider integration amid competitive and regulatory complexities. Capital constraints and execution risks present near-term challenges that will require diligent monitoring as the company pursues growth via acquisitions, alliances, and expanded clinical programs.